HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 07 2021
14 07 2021
Historique:
received:
19
02
2021
accepted:
23
06
2021
entrez:
15
7
2021
pubmed:
16
7
2021
medline:
16
11
2021
Statut:
epublish
Résumé
A major challenge in developing an effective vaccine against HIV-1 is the genetic diversity of its viral envelope. Because of the broad range of sequences exhibited by HIV-1 strains, protective antibodies must be able to bind and neutralize a widely mutated viral envelope protein. No vaccine has yet been designed which induces broadly neutralizing or protective immune responses against HIV in humans. Nanomaterial-based vaccines have shown the ability to generate antibody and cellular immune responses of increased breadth and neutralization potency. Thus, we have developed supramolecular nanofiber-based immunogens bearing the HIV gp120 envelope glycoprotein. These immunogens generated antibody responses that had increased magnitude and binding breadth compared to soluble gp120. By varying gp120 density on nanofibers, we determined that increased antigen valency was associated with increased antibody magnitude and germinal center responses. This study presents a proof-of-concept for a nanofiber vaccine platform generating broad, high binding antibody responses against the HIV-1 envelope glycoprotein.
Identifiants
pubmed: 34262096
doi: 10.1038/s41598-021-93702-x
pii: 10.1038/s41598-021-93702-x
pmc: PMC8280189
doi:
Substances chimiques
HIV Antibodies
0
HIV Antigens
0
HIV Envelope Protein gp120
0
Herpes Simplex Virus Vaccines
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
14494Subventions
Organisme : NIAID NIH HHS
ID : R01 AI145016
Pays : United States
Organisme : NIH HHS
ID : 1R01AI145016
Pays : United States
Organisme : NIH HHS
ID : T32GM008555
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1TR002553
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Science. 2016 Mar 25;351(6280):1458-63
pubmed: 27013733
Immunity. 2013 Jan 24;38(1):176-86
pubmed: 23313589
Proc Natl Acad Sci U S A. 2021 Apr 13;118(15):
pubmed: 33876753
J Virol. 2015 Oct;89(19):9952-61
pubmed: 26202232
AIDS. 2014 Jan 14;28(2):163-9
pubmed: 24361678
EMBO J. 2000 Feb 15;19(4):513-20
pubmed: 10675320
Clin Vaccine Immunol. 2006 Dec;13(12):1307-13
pubmed: 17035513
Eur J Immunol. 2008 May;38(5):1404-13
pubmed: 18389478
Cell. 2016 Sep 8;166(6):1445-1458.e12
pubmed: 27610569
Clin Vaccine Immunol. 2017 Oct 5;24(10):
pubmed: 28814388
Nat Nanotechnol. 2021 Apr;16(4):1-14
pubmed: 32807876
J Virol. 2018 Mar 28;92(8):
pubmed: 29386288
mSphere. 2020 Mar 25;5(2):
pubmed: 32213623
J Virol. 2014 Mar;88(6):3329-39
pubmed: 24390332
Science. 2002 Jun 28;296(5577):2354-60
pubmed: 12089434
J Control Release. 2018 Jul 28;282:120-130
pubmed: 29673645
Stat Med. 2016 Dec 10;35(28):5318-5319
pubmed: 27813200
Lancet Infect Dis. 2019 Feb;19(2):143-155
pubmed: 30509777
Adv Healthc Mater. 2013 Aug;2(8):1114-9
pubmed: 23436779
PLoS One. 2014 Feb 04;9(2):e87572
pubmed: 24504509
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6639-E6648
pubmed: 27702895
J Virol. 2008 Dec;82(24):12449-63
pubmed: 18842730
Immunity. 2020 Sep 15;53(3):548-563.e8
pubmed: 32857950
J Virol. 2019 May 1;93(10):
pubmed: 30842326
J Virol. 2017 Apr 13;91(9):
pubmed: 28202762
Bioconjug Chem. 2014 Aug 20;25(8):1470-8
pubmed: 25020048
Immunity. 2013 Oct 17;39(4):758-69
pubmed: 24035365
ACS Nano. 2012 Feb 28;6(2):1557-64
pubmed: 22273009
Acta Biomater. 2016 Jan;30:62-71
pubmed: 26584836
Immunol Rev. 2017 Jan;275(1):145-160
pubmed: 28133802
J Infect Dis. 2015 Feb 15;211(4):508-17
pubmed: 25170104
J Virol. 2011 Sep;85(18):9555-67
pubmed: 21734046
Immunol Rev. 2017 Jan;275(1):161-182
pubmed: 28133806
Vaccine. 2018 Sep 5;36(37):5600-5608
pubmed: 30087048
Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1080-5
pubmed: 22247289
Cell. 2019 Mar 7;176(6):1420-1431.e17
pubmed: 30849373
Science. 2019 Dec 6;366(6470):
pubmed: 31806786
Biomaterials. 2012 Sep;33(27):6476-84
pubmed: 22695068
Immunity. 2017 Jun 20;46(6):1073-1088.e6
pubmed: 28636956
Vaccine. 2013 Mar 1;31(11):1480-9
pubmed: 23352329
PLoS One. 2013 Sep 26;8(9):e75665
pubmed: 24086607
Nat Mater. 2014 Aug;13(8):829-36
pubmed: 24930032
Biomaterials. 2020 May;241:119903
pubmed: 32143059
Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):622-7
pubmed: 20080728
Vaccines (Basel). 2016 May 13;4(2):
pubmed: 27187483
Biomater Sci. 2020 Jun 21;8(12):3522-3535
pubmed: 32452474
ACS Biomater Sci Eng. 2017 Dec 11;3(12):3128-3132
pubmed: 30740520
Science. 2019 Feb 8;363(6427):649-654
pubmed: 30573546
Nat Med. 2010 Mar;16(3):319-23
pubmed: 20173752
Sci Rep. 2018 Nov 8;8(1):16527
pubmed: 30410003
mSphere. 2018 Jan 10;3(1):
pubmed: 29359183
Immunity. 2016 Sep 20;45(3):483-496
pubmed: 27617678
J Virol. 2015 Mar;89(5):2507-19
pubmed: 25540368
Biomaterials. 2017 Dec;149:1-11
pubmed: 28982051
ACS Biomater Sci Eng. 2017 Feb 13;3(2):153-159
pubmed: 29888321
PLoS Biol. 2020 Jul 14;18(7):e3000411
pubmed: 32663221
Cell Rep. 2016 May 31;15(9):1986-99
pubmed: 27210756
J Virol. 2017 Dec 14;92(1):
pubmed: 29021402
Front Immunol. 2020 Aug 18;11:1855
pubmed: 32973764
J Exp Med. 2017 Aug 7;214(8):2283-2302
pubmed: 28698284
PLoS One. 2016 Jul 21;11(7):e0157391
pubmed: 27442017
Cell. 2019 May 16;177(5):1153-1171.e28
pubmed: 31080066
PLoS One. 2010 Aug 20;5(8):e12303
pubmed: 20808830